PALO ALTO, Calif.--(BUSINESS WIRE)--Mindstrong Health, a startup transforming the diagnosis and treatment of neuropsychiatric disorders, has entered into a partnership with Takeda Pharmaceutical Company Limited (TSE: 4502) to explore the development of digital biomarkers for selected mental health conditions, in particular schizophrenia and treatment-resistant depression. “Takeda shares our goal of using innovative technology to gain insights that will improve outcomes for people living with me.